Open AccessIn vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli
Author(s) -
Dennis G. Delgado,
Carmen J. Brau,
Charles Cobbs,
William E. Dismukes
Publication year - 1979
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.16.6.864
Subject(s) - microbiology and biotechnology , cefoxitin , cefotaxime , proteus mirabilis , providencia , cephalosporin , mezlocillin , enterobacter , azlocillin , carbenicillin , cefamandole , proteus , amikacin , biology , cefazolin , minimum inhibitory concentration , gentamicin , piperacillin , pseudomonas aeruginosa , antibiotics , bacteria , escherichia coli , staphylococcus aureus , biochemistry , gene , genetics
A total of 434 clinical aerobic gram-negative bacillary isolates were tested against LY127935, a new 1-oxa cephalosporin, and compared with other cephalosporins, penicillins, and aminoglycosides by a broth microdilution technique. Cefotaxime (HR756), a new semisynthetic cephalosporin, and LY127935 were more active, and showed lower minimum inhibitory concentrations (ranges, less than or equal to 0.12 to 2.0 micrograms/ml), than cefamandole, cefoxitin, and cefazolin against Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus mirabilis, indole-positive Proteus spp., Serratia marcescens, Providencia spp., and Citrobacter spp. Against P. aeruginosa, pepercillin, azlocillin, and mezlocillin were the most active beta-lactam agents; 64 micrograms/ml inhibited 99, 93, and 87% of the isolates, respectively. LY127935 and cefotaxime at 16 micrograms/ml inhibited 71% of Pseudomonas isolates, whereas the aminoglycosides gentamicin, tobramycin, and amikacin at a concentration of 4 micrograms/ml inhibited 84, 88, and 93%, respectively. Minimum bactericidal concentrations were determined for all isolates and were generally the same as the minimum inhibitory concentrations.